Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) is expected to be announcing its results before the market opens on Friday, November 13th. Analysts expect Bluejay Diagnostics to announce earnings of ($3,520.00) per share for the quarter.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($4.48) EPS for the quarter, beating the consensus estimate of ($14,080.00) by $14,075.52.
Bluejay Diagnostics Price Performance
NASDAQ BJDX opened at $2.81 on Wednesday. The business has a fifty day moving average price of $3.11 and a two-hundred day moving average price of $7.10. Bluejay Diagnostics has a fifty-two week low of $1.84 and a fifty-two week high of $28.00. The stock has a market capitalization of $3.15 million, a PE ratio of -0.40 and a beta of 0.92.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on BJDX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, September 21st. Wall Street Zen downgraded Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, September 14th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.
Read Our Latest Stock Report on BJDX
About Bluejay Diagnostics
Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer. Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.
Read More
- Five stocks we like better than Bluejay Diagnostics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
